id: NEW:baclofen_pharmacotherapy_aud_to_NEW:percent_days_abstinent
name: Baclofen Pharmacotherapy for Alcohol Use Disorder â†’ Percent Days Abstinent from Alcohol
from_node:
  node_id: NEW:baclofen_pharmacotherapy_aud
  node_name: Baclofen Pharmacotherapy for Alcohol Use Disorder
to_node:
  node_id: NEW:percent_days_abstinent
  node_name: Percent Days Abstinent from Alcohol
direction: positive
category: healthcare_access
mechanism_pathway:
- 'Step 1: Baclofen, a GABA-B receptor agonist, is prescribed at doses up to 50-60 mg/day for alcohol
  use disorder treatment'
- 'Step 2: GABA-B receptor activation modulates mesolimbic dopamine pathways involved in alcohol reward
  and reinforcement'
- 'Step 3: Reduced dopaminergic signaling in reward circuits decreases the reinforcing properties of alcohol'
- 'Step 4: Patients experience increased ability to maintain abstinence from alcohol consumption'
- 'Step 5: Higher percent days abstinent reflects improved AUD treatment outcomes'
evidence:
  quality_rating: A
  n_studies: 14
  primary_citation: 'Kazumasa Kotake et al. 2025. "Optimal Dose of Baclofen for the Treatment of Alcohol
    Use Disorder: A Systematic Review and Dose-Response Meta-analysis.." https://doi.org/10.1007/s40263-025-01188-2'
  supporting_citations:
  - Additional citations require full-text access - meta-analysis included 14 randomized controlled trials
  - Studies identified through Cochrane, EMBASE, MEDLINE via PubMed, PsycINFO databases
  - ClinicalTrials.gov and International Clinical Trials Registry Platform searches conducted April 2024
  doi: 10.1007/s40263-025-01188-2
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Baclofen at doses up to 50-60 mg/day increases percent days abstinent in patients with alcohol
  use disorder, representing a medication-assisted treatment approach that addresses the neurobiological
  underpinnings of AUD rather than relying solely on behavioral interventions.
quantitative_effects:
  sample_size: 1344
moderators:
- name: baclofen_dose
  direction: u_shaped
  strength: strong
  description: Benefits observed with increasing doses up to 50-60 mg/day; doses >60 mg/day lacked reliable
    evaluation due to limited data
- name: individual_patient_factors
  direction: strengthens
  strength: moderate
  description: Authors recommend clinicians carefully consider individual patient factors when prescribing
structural_competency:
  equity_implications: This mechanism highlights the importance of healthcare system access to evidence-based
    pharmacotherapy for AUD. Treatment availability is a structural determinant - disparities in access
    to addiction medicine specialists, insurance coverage for AUD medications, and healthcare system capacity
    to prescribe and monitor baclofen therapy can create inequities in treatment outcomes. The focus on
    optimal dosing provides guidance that can improve standardization of care across healthcare settings.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.899164'
  extraction_confidence: high
  prompt_version: 2.1-canonical-validated
